Marksans Pharma Q4: Marksans Pharma delivered a strong performance in the fourth quarter of FY26, with consolidated revenue surging 20.8% year-on-year to Rs 856 crore, up from Rs 709 crore in the corresponding quarter last fiscal.
The pharmaceutical company's operating efficiency saw a massive boost as EBITDA jumped 54% to Rs 195 crore, compared to Rs 127 crore previously, driving a sharp expansion in EBITDA margins to 22.8% from 17.9% year-on-year.
This robust operational growth, further supported by a more than twofold increase in other income to Rs 35.2 crore, trickled down to the bottom line despite a doubling of tax expenses to Rs 51 crore. Consequently, Marksans Pharma reported a stellar 63.6% growth in consolidated net profit, which climbed to Rs 148 crore against Rs 90.5 crore in the same period last year.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.